XTL Biopharmaceuticals Ltd has acquired a stake in U.S.-based iviGene Corporation. The acquisition gives XTL access to iviGene‘s proprietary IVIAT technology for identifying novel drug targets for treating a broad range of infectious diseases. The technology is expected to enable XTL to develop both novel human monoclonal antibody and small molecule drugs for antiviral, antibacterial Read more about XTL Acquires Stake In iviGene[…]